Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

This study is testing the combination of two immunotherapy drugs — epcoritamab and loncastuximab tesirine — for people with large B-cell lymphoma (a type of blood cancer) that has come back or stopped responding to previous treatment. **You may be eligible if...** - You are 18 or older - You have large B-cell lymphoma (including DLBCL or related subtypes) that has relapsed or is no longer responding to treatment - You have measurable disease on imaging - Your heart, liver, kidney, and bone marrow function are adequate **You may NOT be eligible if...** - You have not had any prior treatment for lymphoma - You have active autoimmune disease requiring treatment - You have received prior CAR-T cell therapy within a certain timeframe - You are pregnant or breastfeeding - You have active infections or other serious medical conditions Talk to your doctor to see if this trial is right for you.